Ticlopidine HCl
Catalog No.S1984
Molecular Weight(MW): 300.25
Ticlopidine HCl is an P2 receptor inhibitor against ADP-induced platelet aggregation with IC50 of ~2 μM.
Purity & Quality Control
Choose Selective P2 Receptor Inhibitors
Biological Activity
| Description | Ticlopidine HCl is an P2 receptor inhibitor against ADP-induced platelet aggregation with IC50 of ~2 μM. | ||
|---|---|---|---|
| Targets |
|
||
| In vitro |
Ticlopidine HCl is an antiplatelet drug in the thienopyridine family. Ticlopidine HCl inhibits platelet aggregation by altering the function of platelet membranes by blocking ADP receptors. This prevents the conformational change of glycoprotein IIb/IIIa which allows platelet binding to fibrinogen. [1] Ticlopidine HCl inhibits platelet aggregation and prostaglandin synthesis from endogenous substrate through activating basal and PGE1-stimulated activity of the cyclase, preventing PGE2-induced depression of the cyclase activity and thus increasing platelet c-AMP level. [2] |
||
| In vivo | Ticlopidine HCl inhibits platelet aggregation with IC50 of ~2 μM in men. [1] Ticlopidine HCl, when orally administered to rats, results in activation of basal and prostaglandin E1 (PGE1)-stimulated adenylate cylase activity through increase in affinity of the cyclase in platelet membrane to PGE1, although it failed to affect adenosine- or sodium fluoride-stimulated activity of the enzyme. [2] |
Protocol
Solubility (25°C)
| In vitro | Water | 4 mg/mL (13.32 mM) |
|---|---|---|
| DMSO | 1 mg/mL (3.33 mM) | |
| Ethanol | 1 mg/mL (3.33 mM) |
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Information
| Molecular Weight | 300.25 |
|---|---|
| Formula | C14H14ClNS.HCl |
| CAS No. | 53885-35-1 |
| Storage | powder |
| Synonyms | N/A |
Bio Calculators
Molarity Calculator
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Dilution Calculator
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Molarity Calculator
Clinical Trial Information
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT02133989 | Unknown status | Carotid Stenosis | Samsung Medical Center|Yuyu Pharma, Inc. | June 2014 | Phase 3 |
| NCT01214941 | Completed | Pharmacokinetics|Pharmacodynamics | Turku University Hospital | September 2010 | Phase 4 |
| NCT00862420 | Completed | Peripheral Arterial Disease (PAD) | Sanofi | February 2009 | Phase 3 |
| NCT00821834 | Completed | Stable Angina|Myocardial Infarction | Sanofi | December 2008 | Phase 3 |
| NCT00004727 | Completed | Stroke|Cerebral Infarction | National Institute of Neurological Disorders and Stroke (NINDS) | null | Phase 4 |
Tech Support
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
